Clinical Trials Logo

Shigella clinical trials

View clinical trials related to Shigella.

Filter by:
  • None
  • Page 1

NCT ID: NCT06047821 Recruiting - Diarrhea Clinical Trials

Enterics for Global Health (EFGH)

EFGH
Start date: August 25, 2022
Phase:
Study type: Observational

Diarrhea remains a leading cause of death among young children, with the majority of diarrhea deaths occurring in low- and middle-income countries. Childhood diarrhea caused by a type of bacteria called "Shigella" is responsible for an estimated 60,000 deaths each year and may cause particularly severe illness among children. Currently, there are several promising vaccines to prevent Shigella diarrhea in development, but key information is still needed to inform future vaccine studies. The purpose of this study, titled Enterics for Global Health (or the "EFGH"), is to determine the number and rate of new cases of Shigella diarrhea among children 6 to 35 months of age presenting to health facilities with diarrhea or dysentery. Over a two-year period, the EFGH study will enroll 1,400 children from each of the seven countries: Peru, Pakistan, Bangladesh, Mali, Malawi, Kenya, and The Gambia (9,800 children total).

NCT ID: NCT04078022 Completed - Shigella Clinical Trials

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

Start date: March 2, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether SF2a-TT15 (a monovalent synthetic carbohydrate-based conjugate Shigella vaccine) is safe and effective in the prevention of Shigella infection.

NCT ID: NCT03778125 Enrolling by invitation - Diarrhea Clinical Trials

Multidrug Resistant Shigella Infection in Bangladesh

Start date: December 13, 2018
Phase:
Study type: Observational

The purpose of this project is to systematically collect clinical and nutritional outcomes information on patients treated for Shigella infection so that physicians and clinical laboratories can better define which Shigella infections are "resistant" to antibiotics and which are "susceptible", focusing on azithromycin a last-line drug to treat drug resistant Shigella

NCT ID: NCT01531530 Completed - Shigella Clinical Trials

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

Start date: July 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.

NCT ID: NCT01080716 Completed - Diarrhea Clinical Trials

Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate

Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an inpatient trial to determine the safety, immunogenicity and efficacy of the WRSS1 candidate vaccine in healthy Thai adult volunteers.

NCT ID: NCT00866476 Terminated - Shigella Clinical Trials

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

Start date: January 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.

NCT ID: NCT00866242 Terminated - Shigella Clinical Trials

Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

Start date: January 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.